AstraZeneca PLC (LON:AZN)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 196.51B +18.7% |
| Revenue (ttm) | 46.25B +8.6% |
| Net Income | 7.87B +25.9% |
| EPS | 5.03 +25.8% |
| Shares Out | 1.55B |
| PE Ratio | 25.17 |
| Forward PE | 15.55 |
| Dividend | 2.36 (1.86%) |
| Ex-Dividend Date | Feb 19, 2026 |
| Volume | 1,677,489 |
| Open | 12,736 |
| Previous Close | 12,670 |
| Day's Range | 12,620 - 13,018 |
| 52-Week Range | 10,524 - 15,732 |
| Beta | 0.22 |
| Analysts | Buy |
| Price Target | 15,920.46 (+22.47%) |
| Earnings Date | Jul 27, 2026 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 24 analysts, the average rating for AZN stock is "Buy." The 12-month stock price target is 15,920p, which is an increase of 22.47% from the latest price.
News
AstraZeneca miss ‘clear positive’ for Omeros, says H.C. Wainwright
H.C. Wainwright reiterates a Buy rating on Omeros (OMER) after AstraZeneca (AZN) disclosed that the Phase 3 study of ultomiris in hematopoietic stem cell transplant-associated thrombotic microangiopat...
Omeros up 11% to $10.89 after AstraZeneca study failure
10:11 EDT Omeros (OMER) up 11% to $10.89 after AstraZeneca (AZN) study failure
Astrazeneca Q2 Earnings Call Highlights
Astrazeneca NYSE: AZN reported first-half 2026 revenue growth of 6% at constant exchange rates, or 11% excluding the effects of generic competition on Farxiga and Brilinta, while core earnings per sha...
AstraZeneca drug prices evolving in response to Trump policy, executive says
AstraZeneca has been adjusting its pricing strategy for new drug launches in response to U.S. President Donald Trump's "most-favoured-nation" policy seeking lower drug prices for Americans, a s...
AstraZeneca boss urges western drugmakers to move at ‘Chinese speed'
Europe and US risk being outpaced on innovation, as happened in the car industry, warns Pascal Soriot
AstraZeneca says CLARITY-Gastric01 Phase III trial met dual primary endpoint
Results from the CLARITY-Gastric01 global Phase III trial showed that sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2...
AstraZeneca says ALXN1210-TMA-313 trial did not achieve primary endpoint
AstraZeneca (AZN) reports high-level results from the ALXN1210-TMA-313 Phase 3 clinical trial showed that Ultomiris did not achieve statistical significance for the primary endpoint of event-free surv...
AstraZeneca reports Sone-Ve improved survival in gastric cancers
AstraZeneca (AZN) reports “positive” high-level results from the CLARITY-Gastric01 global Phase III trial showed that sonesitatug vedotin, or Sone-Ve, demonstrated a statistically significant and high...
AstraZeneca Earnings Call Transcript: Q2 2026
Revised summary: Strong H1 2026 with 6% revenue and 11% core EPS growth, driven by innovative medicines and robust pipeline. Oncology and rare disease saw double-digit growth; respiratory and immunology offset generic losses. Confidence in reaching $80B revenue by 2030 remains high, backed by a diversified late-stage pipeline and ongoing investment.
AstraZeneca Quarterly report: Q2 2026
AstraZeneca has published its Q2 2026 quarterly earnings report on July 27, 2026.
AstraZeneca Slides: Q2 2026
AstraZeneca has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 27, 2026.
AstraZeneca reaffirms FY26 revenue, core EPS guidance
Total Revenue is expected to increase by a mid-to-high single-digit percentage; Core EPS is expected to increase by a low double-digit percentage. The Core Tax rate is expected to be…
AstraZeneca ‘on track’ to deliver ambition of $80B in revenue in 2030
06:06 EDT AstraZeneca (AZN) ‘on track’ to deliver ambition of $80B in revenue in 2030
AstraZeneca reports Q2 core EPS $2.63, up 18% at CER
Reports Q2 revenue $15.4B, consensus $15.42B. Pascal Soriot, CEO, AstraZeneca (AZN), said: “In the first half we saw strong performance and continued pipeline delivery, including six key positive Phas...
AstraZeneca raises interim dividend to $1.06 per share
06:03 EDT AstraZeneca (AZN) raises interim dividend to $1.06 per share
AstraZeneca's rare disease drug misses main goal in late-stage trial
AstraZeneca said on Monday its rare disease drug Ultomiris failed a late-stage trial in patients with a blood vessel complication following a stem cell transplant, the latest in a series of setbacks...
AstraZeneca Posts Sales Growth on Oncology Strength
The U.K. drugmaker's revenue rose 5% when adjusted for currency changes, driven by growth in oncology sales.
AstraZeneca CFO: Very confident we will hit $80 billion revenue target
AstraZeneca CFO, Aradhana Sarin, discusses half-year earnings, the company's drug development pipeline, and its oral GLP-1.
Oil price slides as US and Iran pause fire; cancer treatments help AstraZeneca beat profit forecasts – business live
Rolling coverage of the latest economic and financial news Good morning, and welcome to our rolling coverage of business, the financial markets and the world economy. Oil prices have fallen more than ...
AstraZeneca Q2 Pre-tax Profit Drops, Revenues Rise; Confirms FY26 Outlook
(RTTNews) - British drug major AstraZeneca PLC (AZN, AZN.L) reported Monday lower pre-tax pofit in its second quarter, despite higher revenues.
AstraZeneca beats second-quarter profit expectations, holds outlook
AstraZeneca topped second-quarter profit expectations and backed its 2026 forecasts on Monday on demand for its cancer and heart disease therapies, as the drugmaker sought to quell concerns o...
Upcoming Earnings Report: AstraZeneca PLC (AZN) and More Set to Release
Upcoming Earnings Report: AstraZeneca PLC (AZN) and More Set to Release
AstraZeneca Q2 Earnings Preview: Can Tagrisso, Imfinzi And Farxiga Sustain Momentum?
(RTTNews) - AstraZeneca PLC (AZN) is scheduled to report the second-quarter results on July 27, 2026.
AstraZeneca (AZN) Earnings Report Anticipated as Wall Street Closes Mixed
AstraZeneca (AZN) Earnings Report Anticipated as Wall Street Closes Mixed
Pre-Market Earnings Report for July 27, 2026 : AZN, BOH, ARLP, KOF, HOPE, LKFN, HBT, NBN, BMRC, PERF
The following companies are expected to report earnings prior to market open on 07/27/2026. Visit our Earnings Calendar for a full list of expected earnings releases.AstraZeneca PLC (AZN)is reporting ...